Results 81 to 90 of about 3,071,110 (344)

Keratin 19 as a prognostic marker and contributing factor of metastasis and chemoresistance in high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Keratin 19 (KRT19) is overexpressed in high‐grade serous ovarian cancer with high levels of Kallikrein‐related peptidases (KLK) 4–7 and is associated with poor survival. In vivo analyses demonstrate that elevated KRT19 increases peritoneal tumour burden.
Sophia Bielesch, Isabel Vogel, Sina Nokodian, Johanna Moeller, Antonia Blechschmidt, Vicky Hecht, Vanessa Kuentzel, Katharina Thiedig, Melissa Schwab, Oliver Schilling, Holger Bronger, Marion Kiechle, Viktor Magdolen, Tobias Dreyer   +13 more
wiley   +1 more source

Forecasting Mortality Trends: Advanced Techniques and the Impact of COVID-19

Stats
The objective of this research is to evaluate four distinct models for multi-population mortality projection in order to ascertain the most effective approach for forecasting the impact of the COVID-19 pandemic on mortality. Utilizing data from the Human
Asmik Nalmpatian, Christian Heumann, Stefan Pilz   +2 more
doaj   +1 more source

Inequalities in esophageal cancer mortality in Brazil: Temporal trends and projections.

PLoS ONE, 2018
The main objective of the study was to analyze the effect of age, period and birth cohort on esophageal cancer mortality in Brazil and its geographic regions, per sex.
Juliano Dos Santos, Karina Cardoso Meira, Taynãna César Simões, Raphael Mendonça Guimarães, Mauricio Wiering Pinto Telles, Laiane Felix Borges, Auzenda Conceição Parreira de Assis, Maria das Vitorias Silva, Isabelle Ribeiro Barbosa, Angela Carolina Brandão de Souza Giusti, Camila Alves Dos Santos, Dyego Leandro Bezerra de Souza   +11 more
doaj   +1 more source

Fatigue, Inflammation, and Projected Mortality in Heart Failure [PDF]

Journal of Cardiac Failure, 2012
Fatigue is a prominent and poorly understood symptom of heart failure with reduced ejection fraction (HFrEF). The purpose of this study was to determine whether fatigue correlated with immune biomarkers and prognosis.In patients with HFrEF (N = 59) and healthy controls (N = 25), we prospectively measured fatigue (Profile of Mood States), depressive ...
Anne M, Fink, Rosalia C, Gonzalez, Tadeusz, Lisowski, Maria, Pini, Giamila, Fantuzzi, Wayne C, Levy, Mariann R, Piano   +6 more
openaire   +2 more sources

Somatic mutational landscape in von Hippel–Lindau familial hemangioblastoma

Molecular Oncology, EarlyView.
The causes of central nervous system (CNS) hemangioblastoma in Von Hippel–Lindau (vHL) disease are unclear. We used Whole Exome Sequencing (WES) on familial hemangioblastoma to investigate events that underlie tumor development. Our findings suggest that VHL loss creates a permissive environment for tumor formation, while additional alterations ...
Maja Dembic, Anne Nørremølle, Lilian Bomme Ousager, Lars van Brakel Andersen, Marie Louise Mølgaard Binderup, Mads Thomassen   +5 more
wiley   +1 more source

Projection of age-standardised mortality rates for 23 cancer types in India: a nationwide projection until 2030 using autoregressive integrated moving average (ARIMA) models

BMJ Open
Objectives To project the future burden of cancer mortality in India by forecasting age-standardised mortality rates (ASMRs) for 23 major cancer types up to the year 2030, providing crucial evidence for long-term health planning and resource allocation ...
Vivek Verma, Denny John, M S Narassima, Keechilat Pavithran, Ajil Shaji, Dehannathparambil Kottarathil Vijaykumar   +5 more
doaj   +1 more source

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer

Molecular Oncology, EarlyView.
Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni, Antonella Palmese, Stefano Scalera, Laura Cipriani, Davide Mascolo, Patrizia Vici, Teresa Arcuri, Lorena Filomeno, Eriseld Krasniqi, Giovanni Blandino, Giulia Bon, Marcello Maugeri‐Saccà   +11 more
wiley   +1 more source

Differential expression of cancer‐related genes supports prediction of poor response to first‐line treatments in T‐ALL pediatric patients with high minimal residual disease

Molecular Oncology, EarlyView.
In the present work, we have identified a transcriptional signature based on the differential expression of six genes (BCL2&MAST4, HSH2D&LAT2, METRN&PITPNM2) that would facilitate the early detection of T‐cell acute lymphoblastic leukemia (T‐ALL) patients prone to a poor treatment response and could be implemented at diagnosis, along with other risk ...
Antonio Lahera, Laura Vela‐Martín, Pablo Fernández‐Navarro, José Luis López‐Lorenzo, Javier Cornago, Pilar Llamas, Eduardo Pérez‐Gómez, José Luis Marín‐Rubio, Manuel Fresno, Javier Santos, José Fernández‐Piqueras, María Villa‐Morales   +11 more
wiley   +1 more source

Mtwara Regional and District Projections. [PDF]

, 2006
\ud This report presents population projections for the period 2003 to 2025 for Mtwara region and its districts. The projections were made using a Cohort Component Method (Spectrum System), whereby three components responsible for population change ...
Aboud, Said, Amour, B. H., Chuma, A., Chuwa, A. A., Kaimu, A. M., Mbonile, M., Mkai, Cletus P.B., Naimani, G. M., Ngalinda, I, Ntimba, G. L.   +9 more
core  

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source